Ampio's common stock to be listed on NASDAQ Capital Market

May 18 2011

Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE)("Ampio" or the "Company"), a clinical stage developer of new uses for previously approved drugs and new molecular entities ("NMEs"), announces that its common stock has been approved for listing on the NASDAQ Capital Market.  The shares are scheduled to trade under the ticker symbol "AMPE" and the Company understands that trading will commence on that market in the coming days.

"The Company is pleased to make the transition to NASDAQ and raise our profile in the investment community," commented Don Wingerter, Ampio's chief executive officer. "We believe being listed on the Nasdaq Capital Market will provide Ampio with greater visibility, additional liquidity for our common stock, and opportunities to expand our investor base." Pending the listing change, Ampio's common stock will continue to trade on the OTC Bulletin Board.